e-Newsletter – January 2023
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
Search results
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
The latest research news from Retina UK.
Opus Genetics has completed enrolment in its registrational phase 3 clinical trial of OPGx-LCA5, an investigational gene therapy for LCA5-related Leber Congenital Amaurosis (LCA).
Retina UK has a number of online support resources which we offer via social media.
Our Scientific & Medical Advisory Board (SMAB) advises our Board of Trustees in order that they can approve grants for research projects.
Flip pancakes for people living with inherited sight loss. Take on our Flipping Fantastic Fundraising Challenge and try to flip as many pancakes as possible whilst raising money for Retina UK!
Atsena Therapeutics, a clinical-stage gene therapy company, has completed an important but early milestone by selecting the version of ATSN-401 that they will develop as a potential treatment for Stargardt disease, known as the lead clinical candidate.
Our monthly e-Newsletter featuring the latest updates from Retina UK.
A recording of the Retina UK Professionals' Conference on 27 September 2024. The Conference was held at the Pendulum Hotel in Manchester and online.
A recording of the Retina UK Annual Conference on 28 September 2024. The Conference was held at the Pendulum Hotel in Manchester and online.